In this study, the strong association of TGF‐β signaling with the cancer stem cell–specific immune checkpoints implies that inhibition of TGF‐β signaling may impede CD200‐ or CD276‐mediated immune evasion of breast cancer stem cells, which has rarely been described before. The gene discussed is TGFB1; the disease is cancer.